Please login to the form below

Not currently logged in
Email:
Password:

Solvay wins FDA approvable letter for Creon pancreatic enzyme

Belgium-headquartered Solvay Pharmaceuticals has received an approvable letter from the FDA with respect to its New Drug Application (NDA) for Creon (pancrelipase delayed-release capsules), a pancreatic enzyme for the treatment of pancreatic exocrine insufficiency associated with cystic fibrosis and chronic pancreatitis.

Belgium-headquartered Solvay Pharmaceuticals has received an approvable letter from the FDA with respect to its New Drug Application (NDA) for Creon (pancrelipase delayed-release capsules), a pancreatic enzyme for the treatment of pancreatic exocrine insufficiency associated with cystic fibrosis and chronic pancreatitis.

In April 2004, the FDA published a Federal Register Notice requiring all manufacturers of pancreatic enzyme products to obtain NDA approval. Solvay Pharmaceuticals' application is intended to comply with the FDA's guidance, which defines the requirements for approval.

The FDA stated in its letter that the company would need to provide additional clinical data and Chemistry, Manufacturing and Controls (CMC) information prior to approval.

Dr Laurence Downey, president and CEO of Solvay's US arm, said: "We are confident that our ongoing clinical work that was initiated prior to receiving this letter will satisfy the FDA's request. Creon helps meet a critical medical need for thousands of patients who suffer from cystic fibrosis and pancreatic insufficiency and we will continue to work with the Agency to gain approval for this life-sustaining drug."

21st August 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Weber Shandwick

At Weber Shandwick, engagement has always been the cornerstone of health communications.We make health matter. Health is a basic human...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics